4D Molecular Therapeutics (FDMT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

FDMT 4D Molecular Therapeutics

Watchlist

8.010
-0.260-3.14%

Close Oct 31 16:00 ET

8.010
0.0000.00%

Post 19:22 ET

416.28MMarket Cap-3575P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely
Yahoo FinanceOct 30 10:26 ET
4D Molecular Therapeutics Downgraded at Cantor Following Wet AMD Asset Data
Seeking AlphaSep 23 13:41 ET · Ratings
4D Molecular Therapeutics Analyst Ratings
BenzingaSep 23 12:55 ET · Ratings
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
GlobeNewswireSep 23 08:00 ET
Cantor Fitzgerald Downgrades 4D Molecular Therapeutics(FDMT.US) to Hold Rating
Moomoo NewsSep 23 07:31 ET · Ratings
Cantor Fitzgerald Downgrades 4D Molecular Therapeutics to Neutral From Overweight
MT NewswiresSep 23 07:16 ET

Comments

北美深蓝

Jul 23 20:31

$4D Molecular Therapeutics (FDMT.US)$
🌈 静待股价回落，长线标的，观察仓开仓目标价14.85
⭕ Regulation FD Disclosure.
On July 23, 2024, 4D Molecular Therapeutics, Inc. (the “Company”) reported that interim longest available follow up data from the Phase 1 Dose Expansion cohort, Phase 2 Dose Expansion cohort, and Phase 2 Population Extension cohort from its Phase 1/2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration are expected to be presented at a medical conference in Septemb...